MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib

EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting 02.11.2023 / 14:05 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, Novemb...

Related Keywords

Massachusetts , United States , Canada , Boston , California , Planegg , Bayern , Germany , San Diego , American , Julia Neugebauer , Thomas Biegi , Eamonn Nolan , Tim Demuth , Development Officer , Linkedin , Twitter , Hilton Bayfront Hotel , Xencor Inc , Distribution Services , Nasdaq , Lymphoma Society , Drug Administration , Exchange Commission , American Society Of Hematology , Constellation Pharmaceuticals Inc , Sys To Showcase Phase , Oral Presentation , American Society , Annual Meeting , Morphosys Chief Research , Myelofibrosis Symptom Assessment Form , Janus Kinase Inhibitor Treatment Na , Minimal Clinically Important Difference , Anchor Based Analysis , Diffuse Largeb Cell Lymphoma , World Use , Among Racial , Ethnic Minorities , T Cell Engager Significantly Prolongs Survival , Preclinical Lymphoma , Retrospective Study , Characterize Real World Use , Tafasitamab Plus Lenalidomide , Refractory Diffuse Largeb Cell Lymphoma , Life Expectancy , Real World Standard Of Care , Refractory Diffuse Largeb Cell , Sys Events , Constellation Pharmaceuticals , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Prescribing Information , Medication Guide , Patient Information , Important Safety , Morphosy Annual Report , Corporate News , Regulatory Announcements ,